VERAXA Biotech (NASDAQ: VRXA) announced it has received Scientific Advice from Germany’s Paul-Ehrlich-Institute regarding the underlying biology and proposed non-clinical development plan for its lead proprietary BiTAC-TCE cancer therapy program. The regulatory feedback provides greater clarity on its proposed development strategy and indicates that the agency understands the biological rationale behind its dual-targeting, conditionally active BiTAC-TCE platform, representing an early step in advancing the program toward clinical development.
The company also highlighted preclinical data presented at the American Association for Cancer Research Annual Meeting 2026 showing its lead BiTAC-TCE candidate selectively targeted cancer cells expressing both intended targets while sparing cells expressing only one target. According to the company, the studies demonstrated a favorable safety profile with efficacy comparable to a traditional T-cell engager, supporting the potential for an improved therapeutic index.
VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
This regulatory milestone is significant because it de-risks the early development pathway for VERAXA’s BiTAC platform. The Paul-Ehrlich-Institute’s understanding of the biological rationale suggests the agency recognizes the potential of conditionally active T-cell engagers to improve the therapeutic index—a major challenge in cancer immunotherapy. By sparing healthy cells that express only one target, the BiTAC-TCE platform could reduce off-tumor toxicities while maintaining efficacy, addressing a key limitation of traditional bispecific T-cell engagers.
For investors, the feedback reduces regulatory uncertainty and provides a clearer timeline for clinical entry. The positive preclinical data and regulatory alignment position VERAXA to move toward first-in-human studies. However, forward-looking statements in the release caution that actual results may differ materially due to risks and uncertainties, including those in the company’s filings with the SEC. The full press release is available at https://ibn.fm/jpXam and the latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
